The first results of a study on the use of monthly RNAi with ARO-HBV in patients with chronic hepatitis B virus infections indicate that the treatment effectively reduced all measurable viral products, including HBsAg.
MD Magazine® Editorial Staff
Advertisement
Articles by MD Magazine® Editorial Staff
A total of 85% of study participants achieved virologic suppression (viral load
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
2
What We Still Don't Know: Gaps, Phototherapy, and the Future of Pediatric Eczema Care
3
Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD
4
When and How to Escalate Pediatric Atopic Dermatitis Treatment
5